Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ: TELO · Healthcare · Biotechnology

PublicHQ Baltimore, FLCIK 0001971532Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 48DQ —GM —SS 31

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ workforce scale, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$10.4M

Employees

Market cap

$43.7M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$10.4M-$10.4M2025

Total assets$7.3M$7.3M2025

Liabilities$1.4M$1.4M2025

Equity$5.9M$5.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Telomir Pharmaceuticals, Inc. Common Stock earned -$10.4M in FY2025 net income.

Peers · Healthcare

Planet 13 Holdings Inc.45D Atlas Energy Corp.54D BioXcel Therapeutics, Inc.27D PetMed Express, Inc.43D

Key facts

CEOErez Aminov

SectorHealthcare

IndustryBiotechnology

HeadquartersBaltimore, FL

ExchangeNASDAQ: TELO

Employees1

IPO date2019-04-09

Latest filings

8-K2026-06-15 8-K2026-06-08 8-K2026-05-20 10-Q2026-05-14 8-K2026-04-30 8-K2026-04-24 8-K2026-03-31 8-K2026-03-31

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.